A working model for the time sequence of genetic changes in breast tumorigenesis

Journal of the American College of Surgeons

Volumn 194, Issue 2, 2002, Pages 202-216

  Singletary, S Eva ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MCL 1;

BREAST CARCINOGENESIS; CANCER MODEL; CELL DIFFERENTIATION; CELL DIVISION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; ONCOGENE NEU; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TISSUE CULTURE; TUMOR SUPPRESSOR GENE;

EID: 0036161017     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(01)01108-5     Document Type: Article

References (130)

1. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death
2. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
4. Models for early chemoprevention trials in breast cancer
5. Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide
6. A genetic model for colorectal tumorigenesis
7. Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia
8. Genetic alterations during colorectal tumor development
9. Cancer and aging in mice and man
10. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland free mammary fat pads of female C3H mice
11. Risk factors for breast cancer in women with proliferative breast disease
12. Intraductal epithelial proliferation in the human breast - A comparative study
13. Relationship of fibrocystic disease to carcinoma of the breast
14. Atypical epithelial hyperplasia associated with breast cancer and fibrocystic disease
15. The transition from hyperplasia to invasive carcinoma of the breast
16. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study
17. Molecular genetic studies of early breast cancer evolution
18. Intraductal carcinoma. Long term follow-up after treatment by biopsy alone
19. Intraductal carcinoma of the breast: Follow-up after biopsy only
20. Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease
21. Immunohistochemical detection of ras oncogene p21 product in benign and malignant mammary tissue in man
22. Immunohistochemical study of oncogene product ras p21, c-myc, and growth factor EGF in breast carcinomas
23. Molecular lesions involved in the progression of a human breast cancer
24. Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas
25. Ras activation in human breast cancer
26. Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness
27. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type
28. C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance
29. Mutation and cancer: Statistical study of retinoblastomas
30. p53: Tumor suppression through control of the cell cycle
31. Participation of p53 protein in the cellular response to DNA damage
32. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
33. Interaction of the p53-regulated protein gadd45 with proliferating cell nuclear antigen
34. Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle
35. bcl-2: Role in epithelial differentiation and oncogenesis
36. p53 and vascular-endothelial-growth factor expression predicts outcome in 833 patients with primary breast carcinoma
37. Tumor suppressor genes and their alterations in breast cancer
38. p53 mutations in benign breast tissue
39. Modulation of biomarkers in minimal breast carcinoma
40. Biomarkers in early breast neoplasia
41. The retinoblastoma gene in breast cancer: Allele loss is not correlated with loss of gene protein expression
42. Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation
43. Tumor suppressor genes and their roles in breast cancer
44. Loss of heterozygosity at the mannose-6-phosphate insulin-llke growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas
45. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential
46. Expression of the anti-metastatic gene nm23 in human breast cancer: An association with good prognosis
47. The biology of erbB-2/neu-HER-2 and its role in cancer
48. Genetic changes in breast cancer-consequences for therapy?
49. HER2/neu amplification in benign breast disease and the risk of subsequent breast cancer
50. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis
51. The relationship between human epidermal growth-like factor expression and cellular transformation in NIH3T3 cells
52. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer
53. Cripto: A novel epidermal growth factor-related peptide in mammary gland development and neoplasia
54. Detection of amphiregulin and Cripto-1 in mammary tumors from transgenic mice
55. Neu and its ligands: From an oncogene to neural factors
56. Cell cycle control and cancer
57. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation
58. Cdk inhibitors: On the threshold of checkpoints and development
59. Cyclins and cancer II: Cyclin D and Cdk inhibitors come of age
60. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins
61. Direct binding of cydin D to the retinoblastoma gene product and pRb phosphorylation by the cyclin D-dependent kinase. Cdk4
62. Growth suppression by p16inkH requires functional retinoblastoma protein
63. Processing of cydin E differs between normal and tumor breast cells
64. Deregulated cyclin E induces chromosome instability
65. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer
66. Multifacted regulation of cell cycle progression by estrogen; regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function
67. Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: An immunohistochemical study
68. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status
69. Cyclin E, a redundant cyclin in breast cancer
70. Cydin D1 overexpression in a model of human breast premalignancy: Preferential stimulation of anchorage-independent but not anchorage dependent growth is associated with increased cdk2 activity
71. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast
72. Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast
73. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia
74. Cyclins and breast cancer
75. Expression and amplification of cyclin genes in human breast cancer
76. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types
77. Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspirates
78. Analysis of telomerase activity levels in breast cancer: Positive detection at the in situ breast carcinoma stage
79. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues
80. bcl-2 expression in normal breast tissue during the menstrual cycle
81. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas
82. bcl-2 expression in the spectrum of preinvasive breast lesions
83. Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ of the breast?
84. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins
85. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer
86. bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity
87. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling
88. MIB-1 proliferation index in ductal carcinoma in situ of the breast: Relationship to the expression of the apoptosis-regulating proteins bcl-2 and p53
89. Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast
90. Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast
91. The pathway of neoplastic transformation of human breast epithelial cells
92. The role of retinoblastoma and p53 tumor suppressor pathways in human mammary epithelial cell immortalization
93. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7
94. Mutant p53-induced immortalization of primary human mammary epithelial cells
95. Serum-free growth of human mammary epithelial cells: Rapid clonal growth in defined medium and extended serial passage with pituitary extract
96. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types
97. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10
98. A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium
99. Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome
100. Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo(a)pyrene
101. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements
102. The E6 oncoprotein encoded by human papilloma-virus types 16 and 18 promotes the degradation of p53
103. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his)
104. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells
105. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells
106. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells
107. Multiple genetic changes are required for efficient immortalization of different subtypes of normal human mammary epithelial cells
108. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
109. Ability of the HPV 16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity
110. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2
111. Critical steps in breast carcinogenesis
112. Microsatellite instability during the immortalization and transformation of human breast epithelial cells in vitro
113. Molecular basis of breast cell transformation
114. The p53 tumor suppressor gene
115. Genetic mapping of the BRCA1 region on chromosome 17q21
116. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis
117. Detailed analysis of loss of heterozygosity on chromosome band 17q13 in breast carcinoma on the basis of a high resolution physical map with 29 markers
118. Functional roles of chromosomes 11 and 17 in the transformation of human breast epithelial cells in vitro
119. Differential display of reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line, MCF-7
120. Differentiation state and invasiveness of human breast cancer cell lines
121. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma
122. Differentially expressed genes associated with the metastatic phenotype in breast cancer
123. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer
124. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
125. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast
126. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: Functional consequences of their interaction
127. Expression of metastasis-associated genes h-mtsl and nm23 in carcinoma of breast is related to disease progression
128. Prognostic significance of the metastasis-inducing protein S100A4 in human breast cancer
129. Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene
130. Evaluation of the predictive value of Her2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem cell transplantation